Clinical Trial Detail

NCT ID NCT01648348
Title Bevacizumab With or Without Anti-Endoglin Monoclonal Antibody TRC105 in Treating Patients With Recurrent Glioblastoma Multiforme
Recruitment Completed
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications

malignant glioma

Therapies

Carotuximab

Bevacizumab

Age Groups: adult

No variant requirements are available.